$240 Million
Joint Bookrunner
Follow-On
January 2024
$150 Million
Joint Bookrunner
Follow-On
January 2024
$175 Million
Joint Bookrunner
Follow-On
January 2024
Up to $310 Million
Exclusive Financial Advisor
Global Licensing Agreement with Immunome
January 2024
Up to $240 Million
Lead Placement Agent
Private Placement
January 2024
$140 Million
Joint Bookrunner
Follow-On
January 2024
UNDISCLOSED
Exclusive Financial Advisor
Asset Sale to STEMCELL Technologies
Pending
$50 Million
Joint Bookrunner
Follow-On
December 2023
$150 Million
Joint Bookrunner
Follow-On
December 2023
$100 Million
Joint Bookrunner
Follow-On
December 2023
$300 Million
Joint Bookrunner
Follow-On
December 2023
$70 Million
Exclusive Financial Advisor
Series B Financing and Strategic Collaboration with Quest Diagnostics
November 2023